Dr. Thomas Powles, MBBS, MRCP, MD, from Barts Cancer Institute at Queen Mary University of Londonon
February 17, 2025
At the 2025 ASCO Genitourinary Cancers Symposium, the latest findings from the EV-302 study were presented, providing an updated analysis on the efficacy of combining enfortumab vedotin with pembrolizumab (EV+P) versus standard chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).
Key Points from the Enfortumab Vedotin EV-302 study:
- Superior Efficacy: EV+P demonstrated a significant improvement in both progression-free survival (PFS) and overall survival (OS) over chemotherapy. The median PFS was extended to 12.5 months with EV+P from 6.3 months with chemotherapy, while OS increased from 15.9 months to 33.8 months.
- Response Rates: The combination treatment resulted in a confirmed objective response rate (cORR) of 67.5% compared to 44.2% for chemotherapy. The duration of responses was notably longer with EV+P at 23.3 months versus 7 months for chemotherapy.
- Safety Profile: With the extended follow-up, EV+P continued to show a safer profile with fewer high-grade treatment-related adverse events (57.3% vs. 69.5% for chemo). No new safety issues were identified.
- Subgroup Benefits: The benefits were consistent across all patient subgroups, including those eligible or ineligible for cisplatin and those with or without liver metastases.
- Complete Response: For patients achieving a complete response, EV+P offered durable outcomes with no new safety concerns.
Dr. Thomas Powles, MBBS, MRCP, MD, from Barts Cancer Institute at Queen Mary University of London, highlighted the importance of these findings, stating, “Enfortumab vedotin is the first drug beyond chemotherapy and immune therapy to show a significant survival advantage in previously treated advanced urothelial cancer. This is a big step in the right direction for patients with advanced urothelial cancer where treatment options remain quite limited.”
Enfortumab Vedotin EV-302 Conclusion:
This updated analysis from the EV-302 study solidifies EV+P as the new standard of care for first-line treatment in patients with la/mUC. These results not only confirm the initial findings but also underscore the durability of the treatment benefits without compromising safety.
For more details, check out the study’s publication in the Journal of Clinical Oncology and the clinical trial registration number NCT04223856.
Acknowledgments: We thank all the researchers, institutions, and funding bodies for their contributions to this pivotal study.
References:
- J Clin Oncol 43, 2025 (suppl 5; abstr 664). DOI: 10.1200/JCO.2025.43.5_suppl.664
Stay tuned for further updates in the field of urothelial carcinoma research.
Disclaimer: This post is for informational purposes only and should not be considered medical advice. Always consult with a healthcare provider for medical treatment decisions.
Related Articles:
https://meetings.asco.org/abstracts-presentations/243019
